Positron emission tomography for staging and assessment of tumor response of hepatic malignancies

Seminars in Interventional Radiology

Volumn 23, Issue 1, 2006, Pages 21-32

  Hellman, Robert S ^a,b   Krasnow, Arthur Z ^b   Sudakoff, Gary S ^b  

^a FROEDTERT MEMORIAL LUTHERAN HOSPITAL   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Colorectal cancer; FDG; Hepatocellular cancer; PET

Indexed keywords

CARBON 11; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; GALLIUM 67; OXALIPLATIN; YTTRIUM 90;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DRUG HALF LIFE; HUMAN; INTERVENTION STUDY; LIVER CANCER; LIVER CELL CARCINOMA; LIVER METASTASIS; META ANALYSIS; POSITRON EMISSION TOMOGRAPHY; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 33646104193     PISSN: 07399529     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-939838     Document Type: Review

References (37)

1. Bos R, van der Hoeven J, van der Wall E, et al. Biologic correlates of 18-fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002;20:379-387
2. Antoch G, Fruedenberg LS, Beyer T, et al. To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. J Nucl Med 2004;45:56S-65S
3. Wahl R. Principles of cancer imaging with fluorodeoxy glucose. In: Wahl R, Buchanan J, eds. Principles and Practice of Positron Emission Tomography. Philadelphia: Lippincott Williams and Wilkins; 2002:100-110
4. Dimitrakopoulou-Strauss A, Strauss LG, Burger C, et al. Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. J Nucl Med 2004;45:1480-1487
5. Truant S, Huglo D, Hebbar M, et al. Prospective evaluation of the impact of [18F]fluoro-2-deoxy-D-glucose positron emission tomography of respectable colorectal liver metastases. Br J Surg 2005;92:362-369
6. Strasberg SM, Dehdashti F, Siegel BA, Drebin JA, Linehan D. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann Surg 2001;233:293-299
7. Fernandez FG, Drebin JA, Linehan DC, et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004;240:438-450
8. Kinkel K, Lu Y, Both M, et al. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 2002;224:748-756
9. Huebner RH, Park KC, Shepherd JE, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000;41:1177-1189
10. Lonneux M, Reffad AM, Detry R, Kartheuser A, Gigot JF, Pauwels S. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer. Eur J Nucl Med Mol Imaging 2002;29:915-921
11. Kalff V, Hicks RJ, Ware RE, et al. The clinical impact of 18F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med 2002;43:492-499
12. Whiteford MH, Whiteford HM, Yee LF, et al. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum 2000;43:759-767
13. Rohren EM, Paulson EK, Hagge R, et al. The role of F-18 FDG positron emission tomography in preoperative assessment of the liver in patients being considered for curative resection of hepatic metastases from colorectal cancer. Clin Nucl Med 2002;27:550-555
14. Rydzewski B, Dehdashti F, Gordon BA, Teefey SA, Strasberg SM, Siegel BA. Usefulness of intraoperative sonography for revealing hepatic metastases from colorectal cancer in patients selected for surgery after undergoing FDG PET. AJR Am J Roentgenol 2002;178:353-358
15. Numminen K, Isoniemi H, Halavaara J, et al. Preoperative assessment of focal liver lesions: multidetector computed tomography challenges magnetic resonance imaging. Acta Radiol 2005;46:9-15
16. Selzner M, Hany TF, Wildbrett P, et al. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 2004;240:1027-1036
17. Hussain SM, Zondervan PE, Ijzermans JNM, et al. Benign versus malignant hepatic nodules: MR imaging findings with pathologic correlation. Radiographics 2002;22:1023-1039
18. Okazumi S, Isono K, Enomoto K, et al. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med 1992;33:333-339
19. Ho C, Yu SCH, Yeung DWC. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 2003;44:213-221
20. Khan MA, Combs CS, Brunt EM, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000;32:792-797
21. Wudel LJ, Delbeke D, Morris D, et al. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Am Surg 2003;69:117-126
22. Shiomi S, Hishiguchi S, Ishizu H, et al. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol 2001;96:1877-1880
23. Lee JD, Yun M, Lee JM, et al. Analysis of gene expression profiles of hepatocellular carcinomas with regard to 18F-fluorodeoxyglucose uptake pattern on positron emission tomography. Eur J Nucl Med Mol Imaging 2004;31:1621-1630
24. Rose AT, Rose DM, Pinson CW, et al. Hepatocellular carcinoma outcomes based on indicated treatment strategy. Am Surg 1998;64:1128-1134
25. Sugiyama M, Sakahara H, Torizuka T, et al. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol 2004;39:961-968
26. Ruers T, Bleichrodt RP. Treatment of liver metastases, an update on the possibilities and results. Eur J Cancer 2002;38:1023-1033
27. Kostakoglu L, Goldsmith SJ. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med 2003;44:224-239
28. Delbeke D, Martin WH. PET and PET-CT for evaluation of colorectal carcinoma. Semin Nucl Med 2004;34:209-223
29. Antoch G, Vogt FM, Veit P, et al. Assessment of liver tissue after radiofrequency ablation: findings with different imaging procedures. J Nucl Med 2005;46:520-525
30. Vitola JV, Delbeke D, Meranze SG, et al. Positron emission tomography with F-18-fluorodeoxyglucose to evaluate the results of hepatic chemoembolization. Cancer 1996;78:2216-2222
31. Langenhoff BS, Oycn WJG, Jager GJ, et al. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol 2002;20:4453-4458
32. Blokhuis TJ, van der Schaaf MC, van den Tol MP, et al. Results of radio frequency ablation of primary and secondary liver tumors: long-term follow-up with computed tomography and positron emission tomography-18F-deoxyfluroglucose scanning. Scand J Gastroenterol Suppl 2004;241:93-97
33. Anderson GS, Brinkman F, Soulen MC, et al. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med 2003;28:192-197
34. Wong CY, Salem R, Raman S, Gates VL, Dworkin HJ. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI. Eur J Nucl Med Mol Imaging 2002;29:815-820
35. Wong CY, Salem R, Quing F, et al. Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET. J Nucl Med 2004;45:1892-1897
36. Popperl G, Helmberger T, Munzing W, et al. Selective internal radiation therapy with SIR-Spheres in patients with nonresectable liver tumors. Cancer Biother Radiopharm 2005;20:200-208
37. Torizuka T, Tamaki N, Inokuma T, et al. Value of fluorine-18-PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med 1994;35:1965-1969